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Introduction: Therapy comprising 5-fluorouracil, levofolinate, and oxaliplatin is currently the most common
chemotherapy for colorectal cancer. We experienced a successful case of advanced colon cancer and recurrent
breast cancer with 5-fluorouracil, levofolinate, and oxaliplatin therapy.
Case presentation: A 43-year-old Japanese woman who had already undergone surgery three times for bilateral
breast cancer was admitted to our hospital for the treatment of advanced transverse colon cancer. Preoperative
computed tomography demonstrated a swollen lymph node at her right upper clavicle, and fine-needle aspiration
biopsy of the lymph node showed that it was a metastasis from the breast cancer. A laparoscopic-assisted colectomy
was performed and the pathology demonstrated that the final stage was IIIC (T4aN2aM0, Union for International
Cancer Control, 7th edition). The pathological findings and immunohistochemistry showed that the transverse colon
tumor was not a metastatic lesion from the breast cancer, but was a de novo colon cancer. Chemotherapy was
necessary for both the recurrent breast cancer and the Stage IIIC colon cancer. Therapy of 5-fluorouracil,
levofolinate, and oxaliplatin was administered; the therapy included 5-fluorouracil, which is considered to be
effective for both colon and breast cancer. After two courses of 5-fluorouracil, levofolinate, and oxaliplatin, the
lymph node began to shrink and almost completely disappeared after eight courses of 5-fluorouracil, levofolinate,
and oxaliplatin.
Conclusion: We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good
response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as
breast cancer.
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A combination therapy of three drugs, 5-fluorouracil (5FU),
levofolinate (l-LV) and oxaliplatin (L-OHP; FOLFOX) plays
an important role in chemotherapy for colon cancer [1].
We have experienced a successful case in which FOLFOX
therapy, as postoperative adjuvant chemotherapy for lo-
cally advanced colon cancer, was also effective for the
upper cervical lymph node metastasis of a recurrent breast
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A 43-year-old Japanese woman underwent a physical exa-
mination as part of a screening test. She had a notable
medical history (Table 1). She had undergone treatment
for breast cancer three times. Firstly, at the age of 29 years,
she underwent quadrantectomy (Bq) and axillary lymph-
adenectomy (Ax) for left breast cancer. The pathological
findings showed Stage IIA (T2N0M0, TNM Classification
Union for International Cancer Control, 7th edition [2]).
The postoperative therapy included radiation and uracil-
tegafur (UFT) + tamoxifen. Secondly, at the age of 39
years, she underwent Bq and Ax for right breast cancer.
The pathological findings showed Stage IIA (T1cN1aM0).ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Location Procedure Stage Immunohistochemical staining of surgical specimen Adjuvant therapy
ER PR HER2 CK7 CK20
1 29 Lt-breast Bq+Ax IIA (+) (+) (+) (+) (−) Rad, UFT+TAM
2 39 Rt-breast Bq+Ax IIA (−) (−) (+++) (+) (±) Rad, CEF, PTX+Tmab
3 43 Lt-breast Bt+Ax IIA (−) (−) (−) (+) (−)
4 43 T/C LAC IIIC (−) (−) (−) (+) (+) FOLFOX
Ax: Axillary lymphadenectomy, Bq: Quadrantectomy, Bt: Mastectomy, CEF: Cyclophosphamide + epirubicin + 5-fluorouracil, CK: Cytokeratin, ER: Estrogen receptor,
FOLFOX: 5-fluorouracil, levofolinate, and oxaliplatin, HER2: Human epidermal growth factor receptor 2, LAC: Laparoscopic-assisted colectomy, Lt: Left, PR: Progesterone
receptor, PTX: Paclitaxel, Rad: Postoperative radiation therapy, Rt: Right, Stage: TNM Classification Union for International Cancer Control 7th edition, TAM: Tamoxifen,
T/C: Transverse colon, Tmab: Trastuzumab, UFT: Uracil-tegafur. Operative history showing the operative procedure, Stage, the outcome of immunohistochemical staining,
and postoperative therapies.
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phosphamide, epirubicin, and 5FU (CEF), followed by pac-
litaxel + trastuzumab. Thirdly, at the age of 43 years, she
underwent mastectomy and Ax for left breast cancer. The
pathological findings showed Stage IIA (T2N0M0).
Three months after discharge following the third oper-
ation, she visited our department because she was found
positive for fecal occult blood during a screening test. Col-
onoscopy demonstrated a tumor lesion in her transverse
colon with severe stenosis that prevented the endoscope
from passing through the tumor (Figure 1). The biopsy
finding indicated a Group V, poorly differentiated adeno-
carcinoma. A barium enema examination showed cir-
cumferential stenosis (50mm in size) in the transverse
colon (Figure 2). Cervical to pelvic computed tomography
(CT) revealed a swollen lymph node (size: 21×20mm) in
her right supraclavicular region (Figure 3a), abnormalFigure 1 Colonoscopy shows a tumor lesion with severe stenosis at tthickness of her transverse colon, and lymphadenopathy
around the tumor, and no metastasis in her lungs or liver.
18F-fluorodeoxyglucose positron emission tomography
(FDG-PET) showed increased FDG uptake in her right
supraclavicular region, parasternal region and in her trans-
verse colon (Figure 4a). Neck and parasternal ultrasonog-
raphy demonstrated lymphadenopathy (22×19×12mm) in
her right supraclavicular region and several parasternal
lymphadenopathies, approximately 10mm in size. Aspira-
tion biopsy and cytology were performed for her right
supraclavicular lymph node and led to the diagnosis of
Class V adenocarcinoma, which was very similar to the
breast cancer tissues from the third surgery. Therefore,
she was also diagnosed as having recurrent breast cancer.
There were no abnormalities found in laboratory tests,
including tumor markers for colon and breast cancer: car-
cinoembryonic antigen, cancer antigen (CA) 19–9, p53he transverse colon.
Figure 2 Barium enema shows an apple core sign at the transverse colon.
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receptor 2. Consequently, she was diagnosed as having
transverse colon cancer (T3N1H0 cStage IIIA) and recur-
rent breast cancer, and underwent surgery for resection of
the transverse colon cancer. A laparoscopic-assisted par-
tial colectomy was performed. The surgical finding was
Stage IIIB (T4aN1M0) R0. The pathological findingsa b
Figure 3 Cervical computed tomography demonstrates a swollen sup
to 5mm (b: arrow) after FOLFOX.showed Stage IIIC (T4aN2aM0), and the histological type
was moderately differentiated adenocarcinoma (Tub2),
the venous invasion and lymphatic invasion were both
positive, and the tumor size was 50×42mm (Figure 5). Im-
munohistochemical (IHC) staining was performed on the
three breast cancer specimens and the colon cancer tissue,
considering the possibility of metastatic colon cancer fromraclavicular lymph node. The size decreased from 20mm (a: arrow)
a b
Figure 4 Positron emission tomography scan. (a) Positron emission tomography scan shows some 18F-fluorodeoxyglucose uptake in lesions at
the supraclavicular region and parasternal region. (b) However, these lesions vanished completely after 5-fluorouracil, levofolinate, and oxaliplatin.
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alone was cytokeratin 20 positive (Table 1). Therefore the
colon lesion was ultimately diagnosed as a primary colon
cancer. IHC staining was difficult in the right supracla-
vicular lymph node due to the small amount of biopsy
tissue available. Although she developed fever after the
surgery, she recovered with no significant events, and was
discharged on the 23rd postoperative day. As chemo-
therapy was required to treat both the recurrent breast
cancer and the Stage IIIC colon cancer, FOLFOX regimen
including 5FU was selected to treat both cancers, because
5FU had been approved for both cancers in Japan. She
was started on modified FOLFOX6 (5-FU, 400mg/m2
bolus infusion, followed by l-LV 200mg/m2 and L-OHP
85mg/m2 given concomitantly over 2 hours followed by 5
FU 2, 400mg/m2 continuous infusion over 46 hours). She
received 12 cycles of FOLFOX every 2 weeks over the
course of 6 months with 4 failures of L-OHP. Based on
the Common Terminology Criteria for Adverse Events
Version 4.0 [3] she experienced grade 1 nausea that did notFigure 5 Macroscopic finding of resected specimen shows the diffuserequire any treatment. When she exhibited grade 1 increase
of aspartate aminotransferase, grade 2 increase of alanine
aminotransferase, and grade 1 increase of γ-glutamyl trans-
peptidase, the chemotherapy was delayed for 2 weeks. She
also exhibited grade 2 peripheral sensory neuropathy due
to L-OHP-induced neurotoxicity after administration of
the eighth cycle of FOLFOX, and the neuropathy persisted
for more than 14 days. L-OHP was subsequently omitted
from the 9th to 12th cycles of treatment. She had no grade
3 or 4 adverse events. On occasion she had treatment de-
lays for personal reasons. The right supraclavicular lymph
node was not palpable at the end of the second course.
Marked reduction of the lymph node was observed with
CT and ultrasonography at the end of the eighth course
and no abnormal FDG uptake was detected by PET at the
end of the twelfth course (Figures 3b and 4b). CT demon-
strated the significant reduction of the lymph node size
from 20mm to 5mm, and a partial response was then
achieved according to new Response Evaluation Criteria
in Solid Tumors (version 1.1) [4]. Recurrence of breastinvasive type, 50×42mm in size.
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cancer surgery and chemotherapy is ongoing.
Discussion
The medications to treat breast cancer include anticancer
drugs, hormone drugs and molecular target drugs, and
they are commonly used as monotherapies or in com-
bination [5]. Of the anticancer drugs, anthracyclines and
taxanes have played a central role. While fluorinated pyri-
midines have been administered to patients with breast
cancer, they are not administered mainly as key drugs, but
more often as adjuvant chemotherapy in combination
chemotherapy, including cyclophosphamide, methotrexate
and 5FU (CMF) and CEF. Injectable, oral, ointments and
suppositories of fluorinated pyrimidines have been deve-
loped. In particular, the current oral anticancer drugs have
provided a good response rate against breast cancer (cape-
citabine, tegafur-gimeracil-oteracil potassium) [6]. In this
case, we recommended adjuvant chemotherapy after cura-
tive colon cancer resection, because of the pathological
diagnosis as Stage IIIC. At the same time, chemotherapy
for the recurrent breast cancer was also needed. Thus, we
decided to utilize the FOLFOX regimen including 5 FU, a
fluorinated pyrimidine anticancer drug, as a protocol that
was applicable to both colon and breast cancer. FOLFOX
is a regimen that includes a combination of three drugs,
5FU, l-LV and L-OHP, and a large dose of 5FU can be ad-
ministered by intravenous bolus and continuous intraven-
ous infusion. By administering 5FU instead of uracil,
which is incorporated in the nucleic acid synthesis of can-
cer cells, a ternary complex (TC) is formed with a folate-
related substance, l-LV, and thymidylate synthase, thus,
inhibiting deoxyribonucleic acid (DNA) synthesis within
the cancer cells. As a result, the combination of 5FU and
l-LV should increase the antitumor effect in tumors com-
pared with 5FU monotherapy. Folate concentrations are
the highest 2 hours after l-LV administration. Therefore,
intravenous bolus of 5FU at that time results in the pro-
duction of high levels of the TC, and 46-hour continuous
intravenous infusion of 5FU maintains the TC level for a
long time and enhances the inhibition of DNA synthesis
to induce anticancer effects [7]. However, the platinum-
derivative L-OHP produces crosslinks between DNA pu-
rines and inhibits DNA synthesis, resulting in anticancer
effects [8]. FOLFOX is a regimen that improves the re-
sponse rate through a combination of 5FU+l-LV and L-
OHP. FOLFOX is currently specific to colon cancer and is
used for unresectable or metastatic colon cancer, as well
as adjuvant therapy after advanced colon cancer surgery;
playing an important role in chemotherapy for colon can-
cer with a good response rate. However, the platinum-
containing anticancer drugs, platinum-derivatives, are not
applicable for the treatment of breast cancer in Japan.
However, several recent studies have reported that L-OHPhas a good response rate in the treatment of breast cancer.
For example, some studies of the combination of L-OHP
with 5FU and l-LV for recurrent breast cancer have been
conducted in Europe and the United States of America
and have confirmed the safety and efficacy in a Phase II
study [9-11]. While this patient had previously been
treated with fluorinated pyrimidine anticancer drugs, such
as 5FU and UFT, we expected that the addition of l-LV
might increase the anticancer effect. Furthermore, FOL-
FOX often provides a good response in patients who are
resistant to fluorinated pyrimidine anticancer drugs or
5FU+l-LV for colorectal cancer and gastric cancer [12,13].
Based on these considerations, we chose FOLFOX and
consequently achieved a good response.
Conclusions
We treated a patient with Stage IIIC colon cancer that
relapsed after surgery for breast cancer, using FOLFOX
as a postoperative adjuvant chemotherapy and demon-
strated a successful response for recurrent breast cancer.
Thus, we surmise that FOLFOX has the potential to
provide a good response for tumors that are sensitive to
fluorinated pyrimidine and platinum-containing antican-
cer drugs.
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